Trial Profile

A Phase 2a multi-center trial of EOM613 for cancer cachexia

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 15 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

27 May 2026 According to EOM Pharmaceutical media release, the FDA has cleared its Investigational New Drug (IND) application to conduct a three-month Phase 2a clinical study of EOM613 in cachectic cancer patients. The trial is expected to start in the third quarter of 2026.
07 Jan 2026 According to EOM Pharmaceutical media release, company plans to reactivate an Investigational New Drug (IND) application for the treatment of cachectic cancer patients at the FDAs Office of Oncologic Diseases (OOD) with a view to conducting an open-label Phase II trial with Stage 4 cancer patients.The trials Principal Investigator is Azriel Hirschfeld, MD, at Hirschfeld Oncology in Brooklyn.
10 Dec 2021 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com